Cladribine High Dose

Phase 3

Cladribine High Dose is one of 10 therapeutic programs targeting Generalized Myasthenia Gravis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Generalized Myasthenia GravisRecruiting

Generalized Myasthenia GravisPhase 3

Recruiting

Competition

Competitive Landscape

9 competitors in Generalized Myasthenia Gravis

#DrugCompanyPhaseTrials

Zilbrysq

UCB

Phase 3

3 2

Rysodeg

UCB

Phase 3

2 3

Fabhalta

Novartis

Phase 3

1 4

Ultomiris

AstraZeneca

Phase 3

1 5

VEOPOZ

Regeneron

Phase 3

1 6

Cemdisiran

Regeneron

Phase 3

1 7

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 2

1 8

Cladribine Low Dose

Merck & Co.

Phase 3

1 9

Empasiprubart

Argenx

Phase 2

1 10

Cladribine High Dose

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 3Recruiting

Generalized Myasthenia Gravis

NCT06463587

Clinical

Trials by Indication[1]

Generalized Myasthenia Gravis1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06463587·264 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cladribine High Dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Cladribine High Dose. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Merck & Co.

Cladribine High Dose

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Generalized Myasthenia Gravis1 trial

References

Drug Info

Quick Facts

Related News